E
Elaine Kilgour
Researcher at AstraZeneca
Publications - 62
Citations - 3332
Elaine Kilgour is an academic researcher from AstraZeneca. The author has contributed to research in topics: Cancer & Medicine. The author has an hindex of 23, co-authored 47 publications receiving 2634 citations. Previous affiliations of Elaine Kilgour include University College London & University of Manchester.
Papers
More filters
Journal ArticleDOI
AZD4547: An Orally Bioavailable, Potent, and Selective Inhibitor of the Fibroblast Growth Factor Receptor Tyrosine Kinase Family
Paul R. Gavine,Lorraine Mooney,Elaine Kilgour,Andrew Peter Thomas,Katherine Al-Kadhimi,Sarah Beck,Claire Rooney,Tanya Coleman,Dawn Baker,Martine J. Mellor,A. Nigel Brooks,Teresa Klinowska +11 more
TL;DR: The findings show that AZD4547 is a novel selective small-molecule inhibitor of FGFR with potent antitumor activity against FGFR-deregulated tumors in preclinical models and is under clinical investigation for the treatment ofFGFR-dependent tumors.
Journal ArticleDOI
Molecular pathways: fibroblast growth factor signaling: a new therapeutic opportunity in cancer
TL;DR: A growing body of preclinical data shows that inhibition of FGFR signaling can result in antiproliferative and/or proapoptotic effects, both in vitro and in vivo, thus confirming the validity of the FGF/FGFR axis as a potential therapeutic target.
Journal ArticleDOI
Selumetinib Plus Docetaxel Compared With Docetaxel Alone and Progression-Free Survival in Patients With KRAS-Mutant Advanced Non–Small Cell Lung Cancer: The SELECT-1 Randomized Clinical Trial
Pasi A. Jänne,Michel M. van den Heuvel,Fabrice Barlesi,Manuel Cobo,Julien Mazieres,Lucio Crinò,Sergey Orlov,Fiona H Blackhall,Juergen Wolf,Pilar Garrido,A. Poltoratskiy,Gabriella Mariani,Dana Ghiorghiu,Elaine Kilgour,Paul D. Smith,Alexander Kohlmann,David J. Carlile,David Lawrence,Karin Bowen,Johan Vansteenkiste +19 more
TL;DR: There are no specifically approved targeted therapies for the most common genomically defined subset of non–small cell lung cancer (NSCLC), KRAS-mutant lung cancer, and selumetinib to docetaxel alone as a second-line therapy did not improve progression-free survival.
Journal ArticleDOI
High-Level Clonal FGFR Amplification and Response to FGFR Inhibition in a Translational Clinical Trial
Alex Pearson,Elizabeth C Smyth,Irina S. Babina,Maria Teresa Herrera-Abreu,Noelia Tarazona,Clare Peckitt,Elaine Kilgour,Neil R. Smith,Catherine Geh,Claire Rooney,Ros Cutts,James Campbell,Jian Ning,Kerry Fenwick,Amanda Swain,Gina Brown,Sue Chua,Anne L. Thomas,Stephen R. D. Johnston,Mazhar Ajaz,Katherine Anne Sumpter,Angela Gillbanks,David Watkins,Ian Chau,Sanjay Popat,David Cunningham,Nicholas C. Turner,Nicholas C. Turner +27 more
TL;DR: Using cell lines and patient-derived xenograft models, it is shown that high-level FGFR2 amplification initiates a distinct oncogene addiction phenotype, characterized byFGFR2-mediated transactivation of alternative receptor kinases, bringing PI3K/mTOR signaling under FGFR control.
Journal ArticleDOI
FGFR2 Gene Amplification in Gastric Cancer Predicts Sensitivity to the Selective FGFR Inhibitor AZD4547
Liang Xie,Xinying Su,Lin Zhang,Xiaolu Yin,Lili Tang,Xiuhua Zhang,Yanping Xu,Zeren Gao,Kunji Liu,Minhua Zhou,Beirong Gao,Danping Shen,Lianhai Zhang,Jiafu Ji,Paul R. Gavine,Jingchuan Zhang,Elaine Kilgour,Xiaolin Zhang,Qunsheng Ji +18 more
TL;DR: The data support therapeutic intervention with FGFR inhibitors, such as AZD4547, in patients with gastric cancer carrying FGFR2 gene amplification, and enhancement of in vivo antitumor efficacy using AZD 4547 in combination with chemotherapeutic agents.